To the Editor: We read with interest the excellent article of Daugas et al [1] on HAART-related nephropathies and we would like to clarify several points.
Hypotonic fluids should not be used in volume-depleted children
To the Editor: Dr. Friedman recommends that dehydrated children requiring intravenous therapy should receive hypotonic fluids with a sodium concentration of 3 mEq per 100 ml, after initially receiving bolus therapy with isotonic fluid [1] . A recent report revealed that many children treated in this fashion developed acute hyponatremia [2] . Dr. Friedman is also incorrect when stating that most cases of hospital-acquired hyponatremia resulted when "maintenance therapy was applied erroneously." By Dr. Friedman's own calculations, 0.45% sodium chloride would be used for the treatment of dehydration according to the deficit therapy approach. Dr. Friedman offers no data to support the safety of using hypotonic fluid in volume-depleted children. It makes no physiologic sense to administer hypotonic fluids to patients with a hemodynamic stimulus for vasopressin production.
The recommendations of using 3 mEq of sodium chloride per 100 mL of parenteral fluids are based on the sodium content of human and cow milk [3] . This is far less than the sodium content in the standard American diet and has no applicability to the hospitalized child who may have impaired free water excretion. The safety of this approach has never been demonstrated in the hospitalized children. What we do know is that there have been numerous deaths resulting from hypotonic fluid administration, prompting us to recommend the use of 0.9% sodium chloride in parenteral fluid as prophylaxis against hospital-acquired hyponatremia [4] . Dr. Friedman is critical of our recommendations, stating that "high volumes" of fluid could result in fluid overload. We have never
Active vitamin D agents and refractory hyperparathyroidism in dialysis patients
To the Editor: In the March 2005 issue of Kidney International, Nakanishi et al [1] presented a very interesting study showing that only serum levels of fibroblast growth factor-23 (FGF-23) were significantly related to the prognosis of parathyroid function in dialysis patients. The factors they included in their stepwise regression analysis were serum FGF-23, calcium, phosphate, intact PTH, intact osteocalcin, bone-specific alkaline phosphatase levels, age, and dialysis vintage [1] . They did not include treatment with active vitamin D agents, even though the pretreatment serum FGF-23 levels were significantly higher in those patients (47 out of 103) who were receiving vitamin D. A very recent paper by Foley et al [2] showed that parathyroidectomy was associated, among other factors, also with the previous use of IV vitamin D (hazards ratio 2.44, P < 0.0001). Furthermore, we showed that nodular hyperplasia of parathyroid glands was significantly associated with IV calcitriol pulse therapy (CPT) in hemodialysis patients [3] . The simplest explanation for the paradoxic association between this histologic pattern and IV CPT could be that CPT is often attempted as a "final" nonsurgical strategy when parathyroidectomy is being considered [2] . On the contrary, we hypothesized that, paradoxically, long-term IV CPT might be among the factors determining nodular hyperplasia: in fact, a disturbed and/or decreased action of long-term IV CPT at the level of the parathyroid cell might cause progression into the cell cycle and a disinhibition of cmyc expression, leading to a more aggressive nodular type proliferation of parathyroid glands [4] . Therefore, we kindly ask Nakanishi et al to reanalyze their data, including vitamin D treatment in their stepwise regression analysis. CARLO 
